Cautionary tails
- 20 October 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 32 (1), 20-22
- https://doi.org/10.1016/j.annonc.2020.10.469
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and ImplicationsClinical Cancer Research, 2019
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialJournal of Clinical Oncology, 2019
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab TherapyJAMA Oncology, 2019
- Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpointBritish Journal of Cancer, 2018
- Medians and Milestones in Describing the Path to Cancer CuresJAMA Oncology, 2016
- Immuno-oncology combinations: raising the tail of the survival curveCancer Biology & Medicine, 2016
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerThe New England Journal of Medicine, 2012
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast CancerThe New England Journal of Medicine, 2009
- Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology MeetingJAMA, 2003